<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53751">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02018731</url>
  </required_header>
  <id_info>
    <org_study_id>BMD01</org_study_id>
    <nct_id>NCT02018731</nct_id>
  </id_info>
  <brief_title>L-citrulline and Metformin in Becker's Muscular Dystrophy</brief_title>
  <official_title>Pilot Study to Assess the Efficacy of L-Citrulline and Metformin in Adults With Becker's Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the effects of L-citrulline and metformin and their
      combination therapy on muscle function and force in patients with Becker muscular dystrophy
      (BMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, not-randomized open study. The study medication consists of
      L-citrulline and metformin administered orally; 5g citrulline and 500mg metformin tablets
      will be given 3 times daily.

      Half of the patients will be treated with metformin during the first 6 weeks of the study.
      The other patients will receive initially L-citrulline for 6 weeks, before all patients will
      be treated with the combination therapy (metformin and L-citrulline) for another 6 week
      period.

      The study lasts 12 weeks and includes the screening visit and 3 further visits at baseline,
      week 6 and week 12.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean change of motor function measure (MFM) D1 subscore after 6 and 12 weeks</measure>
    <time_frame>week 6 and week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>MFM total score and six minute walking distance (6MWD)</measure>
    <time_frame>week 6 and week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of muscle fat content (MFC) (assessed by MRI)</measure>
    <time_frame>week 6 and week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of muscle metabolism (assessed by dual energy x-ray absorptiometry  (DEXA) and indirect calorimetry)</measure>
    <time_frame>week 6 and week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of laboratory parameters (oxidative and nitrosative stress)</measure>
    <time_frame>week 6 and week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Becker's Muscular Dystrophy (BMD)</condition>
  <arm_group>
    <arm_group_label>Metformin and Metformin &amp; L-Citrulline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1500 mg/d metformin for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-Citrulline and Metformin &amp; L-Citrulline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 g/d L-citrulline for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and Metformin &amp; L-Citrulline</intervention_name>
    <arm_group_label>Metformin and Metformin &amp; L-Citrulline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Citrulline and Metformin &amp; L-Citrulline</intervention_name>
    <arm_group_label>L-Citrulline and Metformin &amp; L-Citrulline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Molecular or immunohistochemical diagnosis of BMD

          -  ambulant at the time point of screening

        Exclusion Criteria:

          -  Participation in another therapeutic BMD study within the last 3 months

          -  Use of L-Arginine, L-Citrulline or Metformin within the last 3 months

          -  Other chronic disease or relevant limitation of renal, liver, heart function
             according to discretion of investigator

          -  known hypersensitivity to L-citrulline or metformin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Fischer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulrike Bonati, MD</last_name>
    <phone>+41617042243</phone>
    <email>ulrike.bonati@ukbb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniela Rubino</last_name>
    <email>daniela.rubino@ukbb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Bonati, MD</last_name>
      <phone>+41617042243</phone>
      <email>ulrike.bonati@ukbb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Rubino</last_name>
      <email>daniela.rubino@ukbb.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 17, 2013</lastchanged_date>
  <firstreceived_date>December 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Becker's Muscular dystrophy</keyword>
  <keyword>BMD</keyword>
  <keyword>Metformin</keyword>
  <keyword>L-citrulline</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
